Navigation Links
Therapix Biosciences to Ring the Nasdaq Stock Market Opening Bell on June 28
Date:6/27/2017

TEL AVIV, Israel, June 27, 2017 /PRNewswire/ -- Therapix Biosciences Ltd. (Nasdaq: TRPX) ("Therapix"), a specialty clinical-stage pharmaceutical company specializing in the development of cannabinoid-based drugs, today announced that the Company will ring The Nasdaq Stock Market Opening Bell in New York, NY on Wednesday, June 28, 2017 in honor of its initial public offering (IPO) of American Depository Shares (ADSs) listed on the Nasdaq Capital Market in March 2017.

Dr. Elran Haber, Ph.D., Chief Executive Officer of Therapix, stated, "We're proud to celebrate the successful uplisting to the Nasdaq Capital Market as Therapix builds recognition in the U.S. markets to grow exposure to a broader and more diverse investor audience. As we ring the opening bell, I would also like to take this moment to acknowledge and thank the employees, investors and partners who have supported Therapix in our journey thus far. With Therapix running two U.S. clinical studies in 2017 and data on one of them to be released this year, today's celebration comes at a landmark point in our timeline."

A live webcast of The Nasdaq Stock Market Opening Bell ceremony will be available at https://livestream.com/nasdaq/live and also on the Investor Relations portion of Therapix's website at www.therapixbio.com.

Therapix began trading on the Nasdaq Capital Market on March 22, 2017, under the symbol "TRPX".

About Therapix Biosciences

Therapix Biosciences Ltd. (Nasdaq: TRPX) is a specialty clinical-stage pharmaceutical company focused on developing technologies and therapeutics based on cannabinoid pharmaceuticals. The Company's clinical pipeline assets follow a de-risked 505(b)(2) regulatory pathway benefitting from Therapix's unique proprietary formulations based on repurposing an FDA approved synthetic cannabinoid (dronabinol). Therapix's lead compound, THX-TS01, is currently in Phase 2 clinical trials for Tourette's Syndrome and the Company intends to initiate a Phase 1 clinical study of THX-ULD01 for the treatment of Mild Cognitive Impairment, for which no FDA-approved therapies currently exist. Please visit our website for more information at www.therapixbio.com.

Contacts

Josh Blacher
Chief Financial Officer
josh@therapixbio.com

Tirth Patel (investors)
Edison Group
tpatel@edisongroup.com


To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/therapix-biosciences-to-ring-the-nasdaq-stock-market-opening-bell-on-june-28-300480633.html


'/>"/>
SOURCE Therapix Biosciences Ltd
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. Therapix Biosciences to Present at Upcoming Scientific and Investor Conferences in June
2. Therapix Biosciences Ltd. Announces Full Exercise of Underwriters Over-Allotment Option
3. Therapix Biosciences Ltd. Announces Closing of U.S. Initial Public Offering of American Depositary Shares; 2,000,000 American Depository Shares Priced at $6.00 per ADS
4. Therapix Biosciences Ltd. Announces Pricing of U.S. Initial Public Offering and NASDAQ Listing
5. Therapix Biosciences Provides Portfolio Update
6. The Israeli Pharma Company Therapix, is Joined by Five Internationally Renowned Experts, From Israel and the World, in the Field of Psychiatry and Tourette
7. 3-V Biosciences to Present Data at the AACR 2017 Annual Meeting in Washington, DC
8. Avelas Biosciences to Present at Needham & Company 16th Annual Healthcare Conference
9. Pressure BioSciences, Inc. Discusses Research Market, Goals and Milestones for First Half of 2017 in New SNNLive Video Interview with StockNewsNow.com
10. Neurocrine Biosciences Announces Conference Call and Webcast to Report Fourth Quarter and Year-End 2016 Results
11. How These Generic Drugs Stocks are Faring? -- Neurocrine Biosciences, Evoke Pharma, SCYNEXIS, and Eagle Pharma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/28/2017)... , Sept. 28, 2017 Cohen Veterans ... advance the use of wearable and home sensors for ... disorders. Early Signal Foundation, a nonprofit organization focused on ... will provide an affordable analytical system to record and ... ...
(Date:9/25/2017)...  EpiVax, Inc., a leader in the fields ... announced the launch of EpiVax Oncology Inc., a ... cancer vaccines. EpiVax has provided $500,000 in seed ... technologies to the new precision immunotherapy venture. Gad ... as Chief Executive Officer. Gad brings over 25 ...
(Date:9/19/2017)... ANN ARBOR, Mich. , Sept. 19, 2017 HistoSonics, Inc., a venture-backed medical ... the precise destruction of targeted tissues, announced three leadership team developments today:   ... Josh Stopek, PhD ... ... Veteran medical device executive ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... Lori R. Somekh, founder of the Law ... organization of elder law and special needs planning attorneys. “Membership in ElderCounsel helps our ... a forum to network with elder law attorneys nationwide,” said Somekh. , ...
(Date:10/13/2017)... BASKING RIDGE, N.J. (PRWEB) , ... October 13, 2017 , ... ... second annual Holly Day Market. Featuring a collection of specialty vendors and unique items ... myriad of personalized and quality-focused health and wellness services offered by the VNA. ...
(Date:10/13/2017)... ... ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, has released a ... books in the Holy Scriptures, Revelation. The Book of Revelation paints a picture of ... have tossed it off as mere rubbish, but Yisrayl Hawkins says that is because ...
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the Mountains to the ... save lost souls in the Philippines. “The Journey: From the Mountains to the Mission ... of the Bible. She has taught all ages and currently teaches a class of ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... sleep apnea using cutting-edge Oventus O2Vent technology. As many as 18 ... characterized by frequent cessation in breathing. Oral appliances can offer significant relief to ...
Breaking Medicine News(10 mins):